Gossamer Bio Inc. reported adjusted earnings per share of $0.04 above Wall Street estimates for the latest quarter, while revenue exceeded analyst projections.
The San Diego-based biopharmaceutical company disclosed financial results that reflected a positive deviation from market expectations. Adjusted earnings per share came in at $0.12, compared with the consensus estimate of $0.08, according to Refinitiv data.
Revenue for the quarter totaled $32.1 million, surpassing the estimated $29.5 million projected by analysts. The company attributed the outperformance to higher product sales and operational efficiencies.
Gossamer Bio’s management highlighted progress in its commercial-stage therapies, including its lead drug, which has driven the revenue growth. The firm also noted ongoing investments in research and development to support pipeline expansion.
Shares of Gossamer Bio were indicated higher in pre-market trading following the results, reflecting investor optimism toward the company’s financial trajectory. The stock’s performance aligns with broader trends in the biotech sector, where earnings surprises often prompt heightened market activity.
The company’s next financial update is scheduled for the following quarter, with analysts closely monitoring its ability to sustain revenue growth and manage operational costs.
